NCT06979908View on ClinicalTrials.gov

A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

July 22, 2026

Study Completion Date

January 22, 2027

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Fruquintinib+Sintilimab+Chidamide

"Fruquintinib: 5 mg orally once daily on days 1-14 of each 21-day cycle (Q3W).~Sintilimab (anti-PD-1): 200 mg intravenously on day 1 of each cycle (first infusion over 60 minutes, subsequent infusions over 30-60 minutes, Q3W).~Chidamide: 30 mg orally twice weekly (BIW; e.g., Monday \& Thursday or Tuesday \& Friday, with ≥3 days between doses), taken 30 minutes after meals."

Trial Locations (1)

Unknown

RECRUITING

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER